Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11422774 | PMC |
| http://dx.doi.org/10.1093/ehjcr/ytae498 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A phase I trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenously administered low-anticoagulant heparin (M6229) in critically ill sepsis patients.
Intensive Care Med Exp
August 2025
Department of Intensive Care Medicine, Amsterdam University Medical Center, University of Amsterdam, Meibergdreef 9, 1105AZ, Amsterdam, The Netherlands.
Background: Histones released in response to cellular injury are important mediators of organ failure and death in sepsis. Preclinical studies demonstrate that neutralization of histones in sepsis is associated with improved outcome. M6229 is a low-anticoagulant heparin able to neutralize histones.
View Article and Find Full Text PDFFirst in man: a novel 355 nm laser plaque ablation system for peripheral artery disease.
Lasers Med Sci
May 2025
Xuan Wu Hospital of the Capital Medical University, Beijing, China.
Objectives: A New Ultra-Low Pulse width 355 nm Solid-State Laser Shows Superior Performance to 308 nm Lasers in Preclinical Trials. Real-world statistics, however, are currently scarce. The purpose of this study is to assess the CLA-355 nm laser system's clinical safety and feasibility in human trials.
View Article and Find Full Text PDFIntracoronary Structural-Molecular Imaging for Multitargeted Characterization of High-Risk Plaque: First-in-Human OCT-FLIm.
JAMA Cardiol
July 2025
Multimodal Imaging and Theranostic Lab, Cardiovascular Center, Korea University Guro Hospital, Seoul, South Korea.
Importance: Fluorescence lifetime imaging (FLIm) is a molecular imaging technique used to visualize the biochemical composition of atherosclerosis. Novel dual-modal imaging using optical coherence tomography (OCT)-FLIm has the potential to provide both microstructural and biocompositional information on coronary plaques; however, it needs validation for clinical application.
Objective: To investigate the clinical feasibility and safety of OCT-FLIm for characterizing plaque compositions in patients with coronary artery disease (CAD) undergoing revascularization therapy.
First-in-human intravascular polarimetric signatures of superficial femoral artery in-stent restenosis lesion.
Eur Heart J Case Rep
September 2024
Department of Cardiovascular Medicine, Osaka Metropolitan University Graduate School of Medicine, 1-4-3 Asahimachi Abenoku, Osaka 545-8585, Japan.
Vascular response following implantation of the third-generation drug-eluting resorbable coronary magnesium scaffold: an intravascular imaging analysis of the BIOMAG-I first-in-human study.
EuroIntervention
September 2024
Klinik für Herz- und Kreislauferkrankungen, Deutsches Herzzentrum München, Technical University Munich, Munich, Germany.
Article Synopsis
- The BIOMAG-I study evaluated the first-in-human resorbable magnesium scaffold (DREAMS 3G) and showed positive outcomes for clinical results and late lumen loss after 12 months.
- The current substudy looked into vascular healing parameters using optical coherence tomography (OCT) and intravascular ultrasound (IVUS), focusing on aspects like strut visibility and neointimal growth.
- Results from 56 patients indicated that almost all scaffold struts became invisible by 12 months, with a favorable vascular healing response, including a significant decrease in protruding neointimal tissue.